MEK (Mitogen-activated protein kinase kinase, MAPKK) is a kinase enzyme which phosphorylates mitogen-activated protein kinases (MAPKs).The downstream transcription factors that control responses like stress signaling, pathogen response, and hormone signaling are phosphorylated as a result of the activated MAPK.
The final protein in the cascade, a MAPK (ERK, p38, or JNK), is activated by the MAPKKK by phosphorylating a serine or threonine residue on a MAPKK. Mitogen-activated protein kinase kinase 3 (MKK3), MKK6, and occasionally MKK4 are primarily responsible for activating the p38 MAPK. Two upstream MAP2Ks, MKK4 and MKK7, control the JNK. Raf and Ras are activated by the highly homologous kinases MEK1 and MEK2, which then activate ERK mitogen-activated protein kinases.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V74094 | (R)-PD 0325901CL | 1003216-77-0 | (R)-PD 0325901CL is an isomer of PD 0325901CL. |
|
V3182 | APS-2-79 | 2002381-25-9 | APS-2-79 (APS-279) is a potent antagonist of MAPK (mitogen-activated protein kinase) with antitumor activity. |
|
V2664 | APS-2-79 HCl | 2002381-31-7 | APS-2-79 HCl (APS279 HCl; APS-279), the hydrochloride salt of APS-2-79, is an antagonist of MAPK (mitogen-activated protein kinase) with anticancer effects. |
|
V3658 | Avutometinib (Ro 5126766) | 946128-88-7 | Avutometinib (also known as Ro-5126766; CH5126766) is a novel, potent, first-in-class dual inhibitor of MEK/RAFmitogen-activated protein kinases (MAPKs) with anticancer activity. |
|
V0458 | AZD8330 (ARRY704; ARRY424704) | 869357-68-6 | AZD8330 (AZD-8330; ARRY-704; ARRY-424704) is an orally bioactive and non-ATP competitive (Allosteric) MEK 1/2 inhibitor with potential anticancer activity. |
|
V0457 | BIX 02188 | 334949-59-6 | BIX02188 (BIX-02188), an indolinone analog, is a novel, highly potent and selective MEK5 inhibitor with the potential to relieve neuropathic pain. |
|
V0450 | BIX 02189 | 1094614-85-3 | BIX02189 is a novel, potent andselective inhibitor of MEK5 with important biological activity. |
|
V33372 | BIX02189 | 1265916-41-3 | BIX02189 is a novel, potent and selective MEK5 inhibitor with an IC50 of 1.5 nM, also inhibits ERK5 catalytic activity with an IC50 of 59 nM. |
|
V97312 | DS03090629 | DS03090629 is an orally available MEK inhibitor that inhibits MEK activity in an ATP-competitive manner. | |
|
V0451 | GDC-0623 (G-868) | 1168091-68-6 | GDC-0623 (G868) is a novel, potent, orally bioactive, selective and non-ATP-competitive (allosteric) inhibitor of MEK1 with potential anticancer activity. |
|
V74088 | GSK1790627 | 871701-87-0 | GSK1790627 is the N-deacetylated metabolite of trametinib. |
|
V4731 | GW284543 | 790186-68-4 | GW284543 (also known as GW-284543; UNC10225170; UNC-10225170) is a novel, potent and selectiveMEK5inhibitor with potential usefulness in cancer treatment. |
|
V116080 | L-783277 | 791807-02-8 | L-783277 (compound 4) is a MEK inhibitor (IC50 = 4 nM). |
|
V93759 | Luvometinib | 2739690-43-6 | Luvometinib is a mitogen-activated protein kinase (MEK) inhibitor with antitumor activity. |
|
V118781 | Luvometinib-d | Luvometinib-d is the deuterated form of Luvometinib. | |
|
V116702 | MAP2K1 L115P Recombinant Human Active Protein Kinase | MAP2K1 (also known as MEK1) is located downstream of the RAF family, and its activation can lead to the activation of ERK1/2. | |
|
V116591 | MAP2K1 P124L Recombinant Human Active Protein Kinase | MAP2K1 encodes mitogen-activated protein kinase 1 (MEK1), which is a key component of the RAS-mitogen-activated protein kinase kinase (RAS/MAPK) signaling pathway. | |
|
V116562 | MAP2K2 Recombinant Human Active Protein Kinase | MAP2K2 (MEK2) is a dual-specific protein kinase belonging to the MAP kinase family. | |
|
V74092 | MEK-IN-6 | 2845151-86-0 | MEK-IN-6 (Example 69) is a MEK inhibitor. |
|
V74090 | MEK-IN-6 hydrate | 2845153-35-5 | MEK-IN-6 hydrate (compound 69) is a MEK inhibitor. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
